Fractyl Health (GUTS) announced that the United States Patent and Trademark Office, USPTO, has issued two new patents that further strengthen the Company’s extensive intellectual property, IP, portfolio protecting its duodenal resurfacing innovations. Fractyl has built its patent portfolio since 2011, and its IP estate now includes 31 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. The two newly issued patents further reinforce the Company’s leadership position in duodenal resurfacing applications. U.S. Patent No. 12,329,439, issued June 17, 2025, and U.S. Patent No. 12,303,185, issued May 20, 2025, both titled “Electrical energy ablation systems, devices and methods for the treatment of tissue,” are directed to ablating duodenal mucosa with various forms of energy, including thermal and non-thermal electrical energy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health Holds Annual Stockholder Meeting
- Biotech Alert: Searches spiking for these stocks today
- Fractyl Health, Bariendo sign non-binding LOI, to offer Revita nationwide
- Innovative Weight Management Solution Drives Buy Rating for Fractyl Health
- Fractyl Health Submits Clinical Trial Application in Europe